Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...
The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...
These bacteria have evolved the ability to resist treatment with antibiotics, and it's making them more deadly and harder to ...
Moberg Pharma's MOB-015 has outstanding clinical trial data, 76% cure rate, double the current standard topical, Jublia. Read ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Despite their promise, these therapies have faced significant regulatory and access challenges. In July, the European ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a ...
EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...
Interaksyon on MSN5h
‘Right of every Filipino’: Generic brand advocates for affordable healthcareHealthcare products provider RHEA Generics is committed to promoting affordable healthcare by offering generic medications ...
(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...
Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback